Loading…

rhEGF/HP-β-CD complex in poloxamer gel for ophthalmic delivery

The purpose of the present study is to prepare chemically and physically stable rhEGF/poloxamer gel and to investigate its possibility of ophthalmic delivery. The rhEGF/HP-β-CD complex markedly increased rhEGF stability compared with rhEGF solution at 4 °C. The poloxamer gel was composed of poloxame...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2002-02, Vol.233 (1), p.159-167
Main Authors: Kim, Eun-Young, Gao, Zhong-Gao, Park, Jeong-Sook, Li, Hong, Han, Kun
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c391t-44e295703e525e963e7d4d99ef08f013899df20c0b6a14e294e793004575d00c3
cites cdi_FETCH-LOGICAL-c391t-44e295703e525e963e7d4d99ef08f013899df20c0b6a14e294e793004575d00c3
container_end_page 167
container_issue 1
container_start_page 159
container_title International journal of pharmaceutics
container_volume 233
creator Kim, Eun-Young
Gao, Zhong-Gao
Park, Jeong-Sook
Li, Hong
Han, Kun
description The purpose of the present study is to prepare chemically and physically stable rhEGF/poloxamer gel and to investigate its possibility of ophthalmic delivery. The rhEGF/HP-β-CD complex markedly increased rhEGF stability compared with rhEGF solution at 4 °C. The poloxamer gel was composed of poloxamer 407 (16%) and poloxamer 188 (14%). Additive of rhEGF/HP-β-CD complexes increased the gelation temperature and 0.5% rhEGF/HP-β-CD complex exhibited a suitable gelation temperature (35.5 °C). The gel strength and bioadhesive force decreased by increasing the rhEGF and HP-β-CD ratio from 1:4 to 1:20 in the complex. The in vitro release of rhEGF from poloxamer gel containing 1:4 rhEGF/HP-β-CD complex was much slower than that of rhEGF solution and faster than that of 1:20 rhEGF/HP-β-CD complex. After ocular administration of poloxamer gels in the rabbit, the concentration of rhEGF in tear declined at a first-order elimination. The poloxamer gel containing rhEGF/HP-β-CD complex increased the area under the concentration–time curve (AUC) of rhEGF in tear fluid compared with gel containing rhEGF solution. 1:20 ratio of rhEGF/HP-β-CD exhibited high AUC, indicating that rhEGF may be retained in the pre-corneal area for prolonged period. Therefore, the poloxamer gel could be applicable for the development of effective ophthalmic delivery.
doi_str_mv 10.1016/S0378-5173(01)00933-4
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71540580</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517301009334</els_id><sourcerecordid>71540580</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-44e295703e525e963e7d4d99ef08f013899df20c0b6a14e294e793004575d00c3</originalsourceid><addsrcrecordid>eNqF0EtOwzAQgGELgaA8jgDKBgSLwDi243hVofKUkEAC1pZxJtTIqYPdIrgWB-FMpLSCJavZfGOPfkJ2KRxToOXJPTBZ5YJKdgj0CEAxlvMVMqCVZDnjslwlg1-yQTZTegGAsqBsnWxQWinJCxiQYRyfX16cXN3lX5_56Cyzoe08vmduknXBh3fTYsye0WdNiFnoxtOx8a2zWY3evWH82CZrjfEJd5ZzizxenD-MrvKb28vr0elNbpmi05xzLJSQwFAUAlXJUNa8VgobqBqgrFKqbgqw8FQaOrccpWIAXEhRA1i2RQ4W73YxvM4wTXXrkkXvzQTDLGlJBQdRQQ_FAtoYUorY6C661sQPTUHPy-mfcnqeRQPVP-U07_f2lh_Mnlqs_7aWqXqwvwQmWeObaCbWpT_HeMULLns3XDjsc7w5jDpZhxOLtYtop7oO7p9TvgFohIhS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71540580</pqid></control><display><type>article</type><title>rhEGF/HP-β-CD complex in poloxamer gel for ophthalmic delivery</title><source>ScienceDirect Journals</source><creator>Kim, Eun-Young ; Gao, Zhong-Gao ; Park, Jeong-Sook ; Li, Hong ; Han, Kun</creator><creatorcontrib>Kim, Eun-Young ; Gao, Zhong-Gao ; Park, Jeong-Sook ; Li, Hong ; Han, Kun</creatorcontrib><description>The purpose of the present study is to prepare chemically and physically stable rhEGF/poloxamer gel and to investigate its possibility of ophthalmic delivery. The rhEGF/HP-β-CD complex markedly increased rhEGF stability compared with rhEGF solution at 4 °C. The poloxamer gel was composed of poloxamer 407 (16%) and poloxamer 188 (14%). Additive of rhEGF/HP-β-CD complexes increased the gelation temperature and 0.5% rhEGF/HP-β-CD complex exhibited a suitable gelation temperature (35.5 °C). The gel strength and bioadhesive force decreased by increasing the rhEGF and HP-β-CD ratio from 1:4 to 1:20 in the complex. The in vitro release of rhEGF from poloxamer gel containing 1:4 rhEGF/HP-β-CD complex was much slower than that of rhEGF solution and faster than that of 1:20 rhEGF/HP-β-CD complex. After ocular administration of poloxamer gels in the rabbit, the concentration of rhEGF in tear declined at a first-order elimination. The poloxamer gel containing rhEGF/HP-β-CD complex increased the area under the concentration–time curve (AUC) of rhEGF in tear fluid compared with gel containing rhEGF solution. 1:20 ratio of rhEGF/HP-β-CD exhibited high AUC, indicating that rhEGF may be retained in the pre-corneal area for prolonged period. Therefore, the poloxamer gel could be applicable for the development of effective ophthalmic delivery.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/S0378-5173(01)00933-4</identifier><identifier>PMID: 11897420</identifier><identifier>CODEN: IJPHDE</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>2-Hydroxypropyl-beta-cyclodextrin ; Animals ; beta-Cyclodextrins ; Biological and medical sciences ; Chemistry, Pharmaceutical ; Complexation ; Cornea - drug effects ; Cyclodextrins - administration &amp; dosage ; Cyclodextrins - chemistry ; Drug Delivery Systems - methods ; Epidermal Growth Factor - administration &amp; dosage ; Epidermal Growth Factor - chemistry ; Excipients - administration &amp; dosage ; Excipients - chemistry ; Gels ; General pharmacology ; Humans ; Hydroxypropyl-β-cyclodextrin ; Male ; Medical sciences ; Ophthalmic delivery ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Poloxamer ; Poloxamer - administration &amp; dosage ; Poloxamer - chemistry ; Rabbits ; Recombinant Proteins - administration &amp; dosage ; Recombinant Proteins - chemistry ; rhEGF</subject><ispartof>International journal of pharmaceutics, 2002-02, Vol.233 (1), p.159-167</ispartof><rights>2002 Elsevier Science B.V.</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-44e295703e525e963e7d4d99ef08f013899df20c0b6a14e294e793004575d00c3</citedby><cites>FETCH-LOGICAL-c391t-44e295703e525e963e7d4d99ef08f013899df20c0b6a14e294e793004575d00c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=13484247$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11897420$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Eun-Young</creatorcontrib><creatorcontrib>Gao, Zhong-Gao</creatorcontrib><creatorcontrib>Park, Jeong-Sook</creatorcontrib><creatorcontrib>Li, Hong</creatorcontrib><creatorcontrib>Han, Kun</creatorcontrib><title>rhEGF/HP-β-CD complex in poloxamer gel for ophthalmic delivery</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>The purpose of the present study is to prepare chemically and physically stable rhEGF/poloxamer gel and to investigate its possibility of ophthalmic delivery. The rhEGF/HP-β-CD complex markedly increased rhEGF stability compared with rhEGF solution at 4 °C. The poloxamer gel was composed of poloxamer 407 (16%) and poloxamer 188 (14%). Additive of rhEGF/HP-β-CD complexes increased the gelation temperature and 0.5% rhEGF/HP-β-CD complex exhibited a suitable gelation temperature (35.5 °C). The gel strength and bioadhesive force decreased by increasing the rhEGF and HP-β-CD ratio from 1:4 to 1:20 in the complex. The in vitro release of rhEGF from poloxamer gel containing 1:4 rhEGF/HP-β-CD complex was much slower than that of rhEGF solution and faster than that of 1:20 rhEGF/HP-β-CD complex. After ocular administration of poloxamer gels in the rabbit, the concentration of rhEGF in tear declined at a first-order elimination. The poloxamer gel containing rhEGF/HP-β-CD complex increased the area under the concentration–time curve (AUC) of rhEGF in tear fluid compared with gel containing rhEGF solution. 1:20 ratio of rhEGF/HP-β-CD exhibited high AUC, indicating that rhEGF may be retained in the pre-corneal area for prolonged period. Therefore, the poloxamer gel could be applicable for the development of effective ophthalmic delivery.</description><subject>2-Hydroxypropyl-beta-cyclodextrin</subject><subject>Animals</subject><subject>beta-Cyclodextrins</subject><subject>Biological and medical sciences</subject><subject>Chemistry, Pharmaceutical</subject><subject>Complexation</subject><subject>Cornea - drug effects</subject><subject>Cyclodextrins - administration &amp; dosage</subject><subject>Cyclodextrins - chemistry</subject><subject>Drug Delivery Systems - methods</subject><subject>Epidermal Growth Factor - administration &amp; dosage</subject><subject>Epidermal Growth Factor - chemistry</subject><subject>Excipients - administration &amp; dosage</subject><subject>Excipients - chemistry</subject><subject>Gels</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Hydroxypropyl-β-cyclodextrin</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Ophthalmic delivery</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Poloxamer</subject><subject>Poloxamer - administration &amp; dosage</subject><subject>Poloxamer - chemistry</subject><subject>Rabbits</subject><subject>Recombinant Proteins - administration &amp; dosage</subject><subject>Recombinant Proteins - chemistry</subject><subject>rhEGF</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><recordid>eNqF0EtOwzAQgGELgaA8jgDKBgSLwDi243hVofKUkEAC1pZxJtTIqYPdIrgWB-FMpLSCJavZfGOPfkJ2KRxToOXJPTBZ5YJKdgj0CEAxlvMVMqCVZDnjslwlg1-yQTZTegGAsqBsnWxQWinJCxiQYRyfX16cXN3lX5_56Cyzoe08vmduknXBh3fTYsye0WdNiFnoxtOx8a2zWY3evWH82CZrjfEJd5ZzizxenD-MrvKb28vr0elNbpmi05xzLJSQwFAUAlXJUNa8VgobqBqgrFKqbgqw8FQaOrccpWIAXEhRA1i2RQ4W73YxvM4wTXXrkkXvzQTDLGlJBQdRQQ_FAtoYUorY6C661sQPTUHPy-mfcnqeRQPVP-U07_f2lh_Mnlqs_7aWqXqwvwQmWeObaCbWpT_HeMULLns3XDjsc7w5jDpZhxOLtYtop7oO7p9TvgFohIhS</recordid><startdate>20020221</startdate><enddate>20020221</enddate><creator>Kim, Eun-Young</creator><creator>Gao, Zhong-Gao</creator><creator>Park, Jeong-Sook</creator><creator>Li, Hong</creator><creator>Han, Kun</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020221</creationdate><title>rhEGF/HP-β-CD complex in poloxamer gel for ophthalmic delivery</title><author>Kim, Eun-Young ; Gao, Zhong-Gao ; Park, Jeong-Sook ; Li, Hong ; Han, Kun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-44e295703e525e963e7d4d99ef08f013899df20c0b6a14e294e793004575d00c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>2-Hydroxypropyl-beta-cyclodextrin</topic><topic>Animals</topic><topic>beta-Cyclodextrins</topic><topic>Biological and medical sciences</topic><topic>Chemistry, Pharmaceutical</topic><topic>Complexation</topic><topic>Cornea - drug effects</topic><topic>Cyclodextrins - administration &amp; dosage</topic><topic>Cyclodextrins - chemistry</topic><topic>Drug Delivery Systems - methods</topic><topic>Epidermal Growth Factor - administration &amp; dosage</topic><topic>Epidermal Growth Factor - chemistry</topic><topic>Excipients - administration &amp; dosage</topic><topic>Excipients - chemistry</topic><topic>Gels</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Hydroxypropyl-β-cyclodextrin</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Ophthalmic delivery</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Poloxamer</topic><topic>Poloxamer - administration &amp; dosage</topic><topic>Poloxamer - chemistry</topic><topic>Rabbits</topic><topic>Recombinant Proteins - administration &amp; dosage</topic><topic>Recombinant Proteins - chemistry</topic><topic>rhEGF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Eun-Young</creatorcontrib><creatorcontrib>Gao, Zhong-Gao</creatorcontrib><creatorcontrib>Park, Jeong-Sook</creatorcontrib><creatorcontrib>Li, Hong</creatorcontrib><creatorcontrib>Han, Kun</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Eun-Young</au><au>Gao, Zhong-Gao</au><au>Park, Jeong-Sook</au><au>Li, Hong</au><au>Han, Kun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>rhEGF/HP-β-CD complex in poloxamer gel for ophthalmic delivery</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2002-02-21</date><risdate>2002</risdate><volume>233</volume><issue>1</issue><spage>159</spage><epage>167</epage><pages>159-167</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><coden>IJPHDE</coden><abstract>The purpose of the present study is to prepare chemically and physically stable rhEGF/poloxamer gel and to investigate its possibility of ophthalmic delivery. The rhEGF/HP-β-CD complex markedly increased rhEGF stability compared with rhEGF solution at 4 °C. The poloxamer gel was composed of poloxamer 407 (16%) and poloxamer 188 (14%). Additive of rhEGF/HP-β-CD complexes increased the gelation temperature and 0.5% rhEGF/HP-β-CD complex exhibited a suitable gelation temperature (35.5 °C). The gel strength and bioadhesive force decreased by increasing the rhEGF and HP-β-CD ratio from 1:4 to 1:20 in the complex. The in vitro release of rhEGF from poloxamer gel containing 1:4 rhEGF/HP-β-CD complex was much slower than that of rhEGF solution and faster than that of 1:20 rhEGF/HP-β-CD complex. After ocular administration of poloxamer gels in the rabbit, the concentration of rhEGF in tear declined at a first-order elimination. The poloxamer gel containing rhEGF/HP-β-CD complex increased the area under the concentration–time curve (AUC) of rhEGF in tear fluid compared with gel containing rhEGF solution. 1:20 ratio of rhEGF/HP-β-CD exhibited high AUC, indicating that rhEGF may be retained in the pre-corneal area for prolonged period. Therefore, the poloxamer gel could be applicable for the development of effective ophthalmic delivery.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>11897420</pmid><doi>10.1016/S0378-5173(01)00933-4</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 2002-02, Vol.233 (1), p.159-167
issn 0378-5173
1873-3476
language eng
recordid cdi_proquest_miscellaneous_71540580
source ScienceDirect Journals
subjects 2-Hydroxypropyl-beta-cyclodextrin
Animals
beta-Cyclodextrins
Biological and medical sciences
Chemistry, Pharmaceutical
Complexation
Cornea - drug effects
Cyclodextrins - administration & dosage
Cyclodextrins - chemistry
Drug Delivery Systems - methods
Epidermal Growth Factor - administration & dosage
Epidermal Growth Factor - chemistry
Excipients - administration & dosage
Excipients - chemistry
Gels
General pharmacology
Humans
Hydroxypropyl-β-cyclodextrin
Male
Medical sciences
Ophthalmic delivery
Pharmaceutical technology. Pharmaceutical industry
Pharmacology. Drug treatments
Poloxamer
Poloxamer - administration & dosage
Poloxamer - chemistry
Rabbits
Recombinant Proteins - administration & dosage
Recombinant Proteins - chemistry
rhEGF
title rhEGF/HP-β-CD complex in poloxamer gel for ophthalmic delivery
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-22T12%3A00%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=rhEGF/HP-%CE%B2-CD%20complex%20in%20poloxamer%20gel%20for%20ophthalmic%20delivery&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Kim,%20Eun-Young&rft.date=2002-02-21&rft.volume=233&rft.issue=1&rft.spage=159&rft.epage=167&rft.pages=159-167&rft.issn=0378-5173&rft.eissn=1873-3476&rft.coden=IJPHDE&rft_id=info:doi/10.1016/S0378-5173(01)00933-4&rft_dat=%3Cproquest_cross%3E71540580%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c391t-44e295703e525e963e7d4d99ef08f013899df20c0b6a14e294e793004575d00c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=71540580&rft_id=info:pmid/11897420&rfr_iscdi=true